Evidence map›Paper›PMID 27387820›Full record

ArticleBiomacromolecules2016

Influence of Molecular Structure on the In Vivo Performance of Flexible Rod Polyrotaxanes.

Christopher J Collins, Yawo Mondjinou, Bradley Loren, Sandra Torregrosa-Allen, Christopher J Simmons, Bennett D Elzey, Nadia Ayat, Zheng-Rong Lu, David Thompson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomacromolecules, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. GdBioconjugate chemistry · 2018
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Christopher J CollinsDepartment of Chemistry, Purdue University , Multi-disciplinary Cancer Research Facility, 1203 W. State Street, West Lafayette, Indiana 47907, United States.
Yawo MondjinouDepartment of Chemistry, Purdue University , Multi-disciplinary Cancer Research Facility, 1203 W. State Street, West Lafayette, Indiana 47907, United States.
Bradley LorenDepartment of Chemistry, Purdue University , Multi-disciplinary Cancer Research Facility, 1203 W. State Street, West Lafayette, Indiana 47907, United States.
Sandra Torregrosa-AllenPurdue University Center for Cancer Research , 201 S. University Street, West Lafayette, Indiana 47907, United States.
Christopher J SimmonsDepartment of Chemistry, Purdue University , Multi-disciplinary Cancer Research Facility, 1203 W. State Street, West Lafayette, Indiana 47907, United States.
Bennett D ElzeyPurdue University Center for Cancer Research , 201 S. University Street, West Lafayette, Indiana 47907, United States.
Nadia AyatDepartment of Biomedical Engineering, Case Western Reserve University , 10900 Euclid Avenue, Cleveland, Ohio 44106, United States.
Zheng-Rong LuDepartment of Biomedical Engineering, Case Western Reserve University , 10900 Euclid Avenue, Cleveland, Ohio 44106, United States.
David ThompsonDepartment of Chemistry, Purdue University , Multi-disciplinary Cancer Research Facility, 1203 W. State Street, West Lafayette, Indiana 47907, United States.
Purdue University West Lafayette · USCase Western Reserve University · USState Street (United States) · US

Funding

Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI John Tesmer · 1985 to 2026
$43.4M
Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Development of Long-circulating, Degradable Gd-Polyrotaxane MR AgentsR21EB017921 · NIBIB · PURDUE UNIVERSITY · PI THOMPSON, DAVID H · 2014 to 2015
$432k
NCATS NIH HHS UL1 TR001108NCI NIH HHS P30 CA023168NIBIB NIH HHS R21 EB017921
6 · The paper itself

Abstract

Polyrotaxanes, a family of rod-shaped nanomaterials comprised of noncovalent polymer/macrocycle assemblies, are being used in a growing number of materials and biomedical applications. Their physiochemical properties can vary widely as a function of composition, potentially leading to different in vivo performance outcomes. We sought to characterize the pharmacokinetic profiles, toxicities, and protein corona compositions of 2-hydroxypropyl-β-cyclodextrin polyrotaxanes as a function of variations in macrocycle threading efficiency, molecular weight, and triblock copolymer core structure. We show that polyrotaxane fate in vivo is governed by the structure and dynamics of their rodlike morphologies, such that highly threaded polyrotaxanes are long circulating and deposit in the liver, whereas lung deposition and rapid clearance is observed for species bearing lower 2-hydroxypropyl-β-cyclodextrin threading percentages. Architecture differences also promote recruitment of different serum protein classes and proportions; however, physiochemical differences have little or no influence on their toxicity. These findings provide important structural insights for guiding the development of polyrotaxanes as scaffolds for biomedical applications.

Indexed as

AnimalsBiocompatible MaterialsCyclodextrinsHemolysisHumansKineticsMaleMiceMice, Inbred BALB CMolecular StructurePoloxamerPolyethylene GlycolsPolymersRotaxanesTissue DistributionBiocompatible MaterialsCyclodextrinsPoloxamerPolyethylene GlycolsPolymerspolyrotaxaneRotaxanes

Identifiers

PMID27387820
PMCPMC5022066
OpenAlexW2471690059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.